Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Depreciation & Amortization (CF) (2018 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Depreciation & Amortization (CF) for 10 consecutive years, with $362000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization (CF) fell 78.03% year-over-year to $362000.0, compared with a TTM value of $4.1 million through Dec 2025, down 36.55%, and an annual FY2025 reading of $4.1 million, down 36.55% over the prior year.
  • Depreciation & Amortization (CF) was $362000.0 for Q4 2025 at Zevra Therapeutics, down from $392000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $1.7 million in Q2 2025 and bottomed at $62000.0 in Q3 2023.
  • Average Depreciation & Amortization (CF) over 5 years is $632500.0, with a median of $331000.0 recorded in 2022.
  • The sharpest move saw Depreciation & Amortization (CF) plummeted 84.42% in 2023, then soared 2508.06% in 2024.
  • Year by year, Depreciation & Amortization (CF) stood at $64000.0 in 2021, then surged by 368.75% to $300000.0 in 2022, then surged by 162.33% to $787000.0 in 2023, then skyrocketed by 109.4% to $1.6 million in 2024, then tumbled by 78.03% to $362000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for ZVRA at $362000.0 in Q4 2025, $392000.0 in Q3 2025, and $1.7 million in Q2 2025.